Jump to Main Content

FDA Alerts

FDA Approves Fedratinib for Myelofibrosis

The Food and Drug Administration approved fedratinib (INREBIC, Impact Biomedicines, Inc.) for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Citations